Loading clinical trials...
Loading clinical trials...
A Phase 1 Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus.
Conditions
Interventions
MEDI6570
Placebo
+1 more
Locations
9
United States
Research Site
Anniston, Alabama, United States
Research Site
Jacksonville, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Port Orange, Florida, United States
Research Site
Honolulu, Hawaii, United States
Research Site
High Point, North Carolina, United States
Start Date
September 28, 2018
Primary Completion Date
July 21, 2020
Completion Date
July 21, 2020
Last Updated
August 24, 2020
NCT07547098
NCT01399385
NCT06675552
NCT00353782
NCT07491315
NCT07487363
Lead Sponsor
MedImmune LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions